Navigation Links
GSK Extends GeneGo License and Adds New Products
Date:2/5/2008

ST. JOSEPH, Mich., Feb. 5 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that GSK has extended their licensing agreement with GeneGo and have added additional capability. This will provide GSK researchers in Bioinformatics, R&D and clinical studies with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo's flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GSK will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating interactive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

"We have a good working relationship with GSK developing new products such as our pay as you go 1-2-3 Workflow," said Julie Bryant, GeneGo's VP of Business development. "We will continue to work closely developing new functionality, tools and content for GSK."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Extends Tender Offer for Ventana
2. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
3. Organon Extends MetaCore License and Adds MetaLink
4. NASA Extends Cooperative Agreement With NSBRI
5. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
6. Roche Extends Tender Offer for Ventana
7. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
8. GeneGo Integrates With Cytoscape
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
10. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
11. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... A leader in ... Kong. , Nerium International is proud to introduce its Age-Defying Night Cream, NeriumAD™ ... Formula to consumers across Hong Kong. The luxury skincare products contain innovative ingredients ...
(Date:2/17/2017)... IPSWICH, Mass. , Feb. 17, 2017 /PRNewswire/ ... a small tumor had a mutation-conferring resistance to ... treatment. Recently, genomics research has focused on finding ... — or even from circulating tumor DNA in ... identify new oncology therapeutics. Unfortunately, however, ...
(Date:2/16/2017)... , ... February 16, 2017 , ... Avomeen & MichBio ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, ... member organization. They provide an opportunity to interact with peers, make new connections and ...
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):